We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Launches Newest Version of Remisol Advance at AACC

By LabMedica International staff writers
Posted on 01 Aug 2013
Beckman Coulter, Inc. More...
(Brea, CA, USA) has released the newest, most advanced version of Remisol Advance data management system, v1.7. This software product streamlines laboratory workflow and the management process with improved sample tracking, results archiving, and consolidation of patient test information from multiple instruments in the lab or from multiple labs in the hospital network.

Remisol Advance v1.7 unifies data management by featuring a 166% increase in sample data processing throughput and a 122% increase in sample data storage from the previous version. It helps optimize lab operations by improving results reporting turnaround times, and standardizing laboratory workflow. The new version features increased device connectivity—up to 128 instruments can now be connected to a single server. The lab may connect to Beckman Coulter analyzers as well as selected third-party instruments.

"Remisol Advance v1.7 offers scalability, security, and standardization across the lab enterprise offering benefits such as multisite connectivity, modules to support lab operations and now, third-party connectivity," said Erik Johnson, Beckman Coulter Diagnostics, director, Automation and Informatics Product Management.

Remisol Advance offers an optional Extended Quality Control (EQC) module, which enhances the laboratory quality control process even further, and features intuitive step-by-step creation of protocols.

This new version of Remisol Advance v1.7 was demonstrated at the 2013 AACC annual meeting held in Houston (TX, USA), from July 28–August 1, 2013

Related Links:

Beckman Coulter, Inc.



New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automatic CLIA Analyzer
Shine i6000
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.